ANDA 78940, held by Actavis Elizabeth. Atomoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 78940 (Atomoxetine Hydrochloride), held by Actavis Elizabeth, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 11, 2012 | Original application | Tentative approval | None posted |
| Atomoxetine Hydrochloride18MG · capsule;oral | Atomoxetine Hydrochloride | None (tentative approval) |
| Atomoxetine Hydrochloride25MG · capsule;oral | Atomoxetine Hydrochloride | None (tentative approval) |
| Atomoxetine Hydrochloride40MG · capsule;oral | Atomoxetine Hydrochloride | None (tentative approval) |
| Atomoxetine Hydrochloride60MG · capsule;oral | Atomoxetine Hydrochloride | None (tentative approval) |
| Atomoxetine Hydrochloride80MG · capsule;oral | Atomoxetine Hydrochloride | None (tentative approval) |
| Atomoxetine Hydrochloride100MG · capsule;oral | Atomoxetine Hydrochloride | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters